Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control
  1. Home
  2. Publications
  3. Supplementary Figure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control

Supplementary Figure 1 from Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control

Authors:
  • PWPatrick A.A. Weber
    Patrick A.A. Weber
  • MPMario Perro
    Mario Perro
  • VNValeria G. Nicolini
    Valeria G. Nicolini
  • KHKlas Hatje
    Klas Hatje
  • SJSilvia Jenni
    Silvia Jenni
  • SBStefanie Briner
    Stefanie Briner
  • EBEsther Bommer
    Esther Bommer
  • MTManuela Tanner
    Manuela Tanner
  • SPSylvain Pilet
    Sylvain Pilet
  • THTamara Hüsser
    Tamara Hüsser
  • EYEmilio Yángüez
    Emilio Yángüez
  • SCStanford Chen
    Stanford Chen

Open Access
Publisher website
Google Scholar
  • 9 July 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/2767-9764.32947272
Abstract
Tobemstomig is refractory to drug-shaving by macrophages
Keywords
  • ANTIBODY IMMUNOTHERAPY
  • CHECKPOINT BLOCKADE
  • IMMUNE CELLS AND THE MICROENVIRONMENT
  • IMMUNOTHERAPY
  • TUMOR MICROENVIRONMENT
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.